Medical Breakthroughs Reported by Ivanhoe.com. Click here to go to the homepage.
Be the First to Know. Click here to subscribe FREE!
Search Reports: Use quotation marks around your multi-word search terms in the box below to perform search of Ivanhoe.com.
Advances in health and medicine.Use " marks around search terms
 
What's New
News Flash
Discussion
healthchannelnews
  Alternative Health
Arthritis
Asthma & Allergies
Autism
Breast Cancer
Cancer
Cardiovascular Health
Children's Health
Dental Health
Diabetes
Fertility & Pregnancy
Men's Health
Mental Health
Multiple Sclerosis
Neurological Disorders
Nutrition & Wellness
Orthopedics
Pet Health
Robotics
Seniors' Health
Sports Medicine
Vision
Women's Health
Advances in health and medicine.
Click here to sign up for Medical Alerts!
Click below to access other news from Ivanhoe Broadcast News.
  Click here to get Ivanhoe's Medical Headline RSS feed Click here to listen to Ivanhoe's Medical Podcasts
Useful Links
Play It Again, Please
E-Mail a Friend
Order Books Online
Inside Science
Smart Woman
Advances in health and medicine.
Smart Woman Home
Click here to read the story
Click here to read the story
Click here to read the story
Smart Woman Home
Advances in health and medicine.
Click below to learn about Ivanhoe.
  Awards
About Us
Contact Us
Employment
Feedback
Ivanhoe FAQ
Our TV Partners
Travel Calendar
Advances in health and medicine.
Ivanhoe celebrates 20 years of medical news reporting reaching nearly 80 million TV households each week. Click here to learn more...
Advances in health and medicine.
Marjorie Bekaert Thomas
Publisher/President
Advances in health and medicine.
Advertisement
Diabetes Channel
Reported April 14, 2014

Drug Beneficial to Diabetics with Kidney Disease

(Ivanhoe Newswire) – A drug called atrasentan provides health benefits for patients with both diabetes and kidney disease, according to a new study. The findings suggest atrasentan may help maintain the well-being of patients who are at high risk of experiencing serious medical problems.

In two identical studies, 211 patients who had both type 2 diabetes and kidney disease were given either placebo, 0.75 mg/day of atrasentan, or 1.25 mg/day of atrasentan for 12 weeks. The researchers found that the low dose of atrasentan (.75 mg/day) lowered urinary protein excretion (albuminuria) by 36 percent without major side effects. The drug also lowered blood pressure and cholesterol levels. The higher dose lowered albuminuria, but caused more fluid retention.

“Although this study demonstrates that atrasentan treatment results in clinically significant albuminuria reduction with minimal fluid overload-related or cardiovascular side effects, a larger study on hard renal and/or cardiac outcomes is needed to further support these findings,” Dick de Zeeuw, MD, at University Medical Center Groningen, in the Netherlands, was quoted as saying.

For more information, go to:

http://jasn.asnjournals.org/content/early/2014/04/09/ASN.2013080830.abstract?sid=3c4b0eda-3a5c-425b-a22a-79db3f566047

SOURCE: Journal of the American Society of Nephrology (JASN), April 2014

Want to be the FIRST TO KNOW?

Click Here for a free weekly email with Ivanhoe's latest Medical Breakthroughs.

 

 

Related Articles in Latest Medical News:

[ Back to Diabetes Channel Home ]

MEDICAL ALERT!
Stay up to date on Diabetes. We can notify you every time there is a medical breakthrough. Click here to sign up.
EDITOR'S CHOICE
Most Recent Videos

Follow Us On:

Click here to go to Ivanhoe's Twitter page Click here to go to Ivanhoe's Facebook page Click here to go to Ivanhoe's YouTube page
Advertisement

Home | What's New | News Flash | Search/Latest Medical News | E-Mail Medical Alerts!
Ivanhoe FAQ | Privacy Policy | Our TV Partners | Awards | Useful Links | Play It Again, Please
RSS Feeds | Advertising/Sponsorships | Content Syndication | Reprints

Advances in health and medicine.
webdoctor@ivanhoe.com
Copyright © 2014 Ivanhoe Broadcast News, Inc.
2745 West Fairbanks Avenue
Winter Park, Florida 32789
(407) 740-0789

P.O. Box 865
Orlando, Florida 32802

Premium Content in Latest Medical News Denotes Premium Content in Latest Medical News